NMTRC

Clinical Trials

We are actively recruiting for specific clinical studies. Click on a specific study for more information. If you are interested in participating in one of the trials below, please contact Genevieve Bergendahl at 616-234-5707 or via email, or one of the contacts at our participating hospitals.

Phase	NMTRC#	Trial Name	Status
Feasibility	NMTRC008	A Feasibility Trial Using Molecular-Guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancer	Open
Phase II	V0706	Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma	Open
Phase I	NMTRC 001	Molecular Guided Therapy for Refractory or Recurrent Neuroblastoma	Completed
Phase I	NMTRC 002	DFMO alone and in combination with Etoposide for Relapsed or Refractory Neuroblastoma	Completed
Phase II	NMTRC 003	Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission	Open
Phase I/II	NMTRC 004	Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma	Open
Phase II	NMTRC 005	Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma	Open
Compassionate Use	NMTRC 006	A Compassionate Use Trial of DFMO as a Single Agent	Open
Biology	NMTRC 00B	A Molecular Analysis of Pediatric Tumors with Establishment of Tumor Models and a Tissue Biology Study	Open
Phase I	TPI-287-11	TPI 287 as a Single Agent and in Combination With Temozolomide in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma	Completed
Pilot	NMTRC001P	Feasibility of Using Molecular-Guided Therapy in Patients With Refractory or Recurrent Neuroblastoma	Completed
Phase I	V0610	Nifurtimox for Relapsed or Refractory Neuroblastoma	Completed